All In Biotech

Drug Trial Radar · NCT00955968

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

IMPAACT 1077HS: HAART Standard Version of the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study

Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,653 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,653

Actual

Start

Jan 1, 2010

Primary completion

Aug 31, 2016

Study completion Aug 31, 2016

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Aug 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized strategy trial conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but did not otherwise meet criteria to initiate HAART for their own health. The study was designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduced morbidity and mortality compared to discontinuation and re-initiation of HAART when protocol specified criteria were met.

Conditions

  • HIV Infection

Interventions

  • Highly active antiretroviral therapy (HAART)Drug

    A combination of three or more HIV medications belonging to two or more drug classes. The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or DeathTime frame: From study entry to study termination, all participants were followed until July 7, 2015 (an average of 125 weeks of follow-up).

Locations

50 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Southern California MCA Center (5048)

    Alhambra, California

  • David Geffen School of Medicine at UCLA (5112)

    Los Angeles, California

  • UCSD Mother-Child-Adolescent HIV Program (4601)

    San Diego, California

  • Harbor (UCLA) Medical Center (5045)

    Torrance, California

  • University of Colorado (5052)

    Aurora, Colorado

  • Howard University (5044)

    Washington D.C., District of Columbia

  • Georgetown University (1008)

    Washington D.C., District of Columbia

  • Washington Hospital Center (5023)

    Washington D.C., District of Columbia

  • Children's Diagnostic and Treatment Center (5055)

    Fort Lauderdale, Florida

  • University of Florida at Jacksonville (5051)

    Jacksonville, Florida

  • University of Miami Pediatric/Perinatal Clinical Research Site (4201)

    Miami, Florida

  • University of South Florida at Tampa (5018)

    Tampa, Florida

  • Ann & Robert H Lurie Children's Hospital of Chicago (4001)

    Chicago, Illinois

  • Tulane University (5095)

    New Orleans, Louisiana

  • Johns Hopkins University School of Medicine (5092)

    Baltimore, Maryland

  • Boston Medical Center (5011)

    Boston, Massachusetts

  • Wayne State University/Children's Hospital of Michigan (5041)

    Detroit, Michigan

  • Metropolitan Hospital (5003)

    New York, New York

  • SUNY Stony Brook University Medical Center (5040)

    Stony Brook, New York

  • Bronx-Lebanon Hospital Center (5114)

    The Bronx, New York

  • Jacobi Medical Center (5013)

    The Bronx, New York

  • Duke University Medical Center (4701)

    Durham, North Carolina

  • Pitt CRS (1001)

    Pittsburgh, Pennsylvania

  • St Jude Children's Research Hospital (6501)

    Memphis, Tennessee

  • Baylor College of Medicine Texas Children's Hospital (3801)

    Houston, Texas

  • Seattle Children's Hospital (5017)

    Seattle, Washington

  • Hospital General de Agudos (5082)

    Buenos Aires, Argentina

  • Gaborone Prevention/Treatment Clinical Research Site (12701)

    Gaborone, Botswana

  • Molepolole Prevention/Treatment Clinical Research Site (12702)

    Gaborone, Botswana

  • School of Medicine, University of Minas Gerais - FUNDEP (5073)

    Belo Horizonte, Brazil

  • University Caxias do Sul (5084)

    Caxias do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao (5117)

    Porto Alegre, Brazil

  • Hospital Santa Casa (5098)

    Porto Alegre, Brazil

  • Hospital dos Servidores do Estado (5072)

    Rio de Janeiro, Brazil

  • Hospital Geral De Nova Igaucu (5097)

    Rio de Janeiro, Brazil

  • Instituto de Puericultura E Pediatria Martagao Geseira - FUJB (5071)

    Rio de Janeiro, Brazil

  • Ribeirao Preto Medical School, University of Sao Paulo (5074)

    São Paulo, Brazil

  • Guangxi Center for HIV/AIDS Prevention and Control (30274)

    Nanning, Guangxi, China

  • Les Centres GHESKIO (30022)

    Port-au-Prince, Haiti

  • IMPACTA Barranco Clinical Research Site (11301)

    Lima, Peru

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.